scispace - formally typeset
Journal ArticleDOI

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.

Hossein Ardeschir Ghofrani, +76 more
- 01 Oct 2017 - 
- Vol. 5, Iss: 10, pp 785-794
Reads0
Chats0
TLDR
In MERIT-1, macitentan significantly improved PVR in patients with inoperable CTEPH and was well tolerated, and resting PVR at week 16, expressed as percentage of PVR measured at baseline.
About
This article is published in The Lancet Respiratory Medicine.The article was published on 2017-10-01. It has received 189 citations till now. The article focuses on the topics: Macitentan & Placebo-controlled study.

read more

Citations
More filters
Journal ArticleDOI

Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.

TL;DR: The achievements and unresolved problems of PAH-targeted therapy for CTEPH over the last decade are summarized.
Journal ArticleDOI

Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension

TL;DR: Chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thrombolic pulmonary vascular disease (CTED) are rare manifestations of venous thrombinopathy as discussed by the authors.
Journal ArticleDOI

Chronic Thromboembolic Pulmonary Hypertension-Management Strategies and Outcomes.

TL;DR: D diagnosis remains challenging given the lack of early clinical signs and overlap with other cardiopulmonary conditions, but use of riociguat has shown promising improvements in functional outcomes up to 2 years after initiation.
Journal ArticleDOI

Chronic Thromboembolic Pulmonary Hypertension: An Update

TL;DR: Pulmonary endarterectomy (PEA) reduces pulmonary vascular resistance, making it the treatment of choice and should be offered to operable CTEPH patients, as significant symptomatic and prognostic improvement has been observed.
Journal ArticleDOI

Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going

TL;DR: The present uses of endothelin receptor antagonists and the advancements in the development of future treatment options are highlighted, thereby providing an overview ofendothelin research over the years and its future scope.
References
More filters
Journal ArticleDOI

Special article2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension

TL;DR: This article is being published concurrently in the European Heart Journal and the European Respiratory Journal and is identical except for minor stylistic and spelling differences in keeping with each journal’s style.
Journal ArticleDOI

Inhaled iloprost for severe pulmonary hypertension.

TL;DR: Inhaled Iloprost is an effective therapy for patients with severe pulmonary hypertension and hemodynamic values were significantly improved at 12 weeks when measured after iloprost inhalation, and were significantly worse in the placebo group.
Related Papers (5)